nanexa

INTERIM REPORT JANUARY-JUNE 2023

NANEXA AB (PUBL)

Nanexa AB (PUBL)

Significant events during the second quarter 2023

- Nanexa AB announced in June that recruitment and dosing have been completed in the Phase 1 study involving NEX-20. Since December 2022, single doses of NEX-20 have been administered to healthy volunteers in three consecutive escalating dose groups. Pharmacokinetic profile, safety, and tolerability data have been collected for the final dose group, with results expected to be presented in the upcoming autumn.
- Nanexa entered into an agreement with the contract research organization (CRO) Profil in Neuss, Germany, ahead of the upcoming phase I study involving NEX-22, a monthly depot of liraglutide intended for the treatment of type 2 diabetes and, eventually, obesity. Profil specializes in early clinical studies within the fields of diabetes and obesity, and enjoys a strong global reputation for its execution of clinical research in these indications.

Significant events after the end of the period

- In August, Nanexa obtained pharmacokinetic data from the Phase 1 clinical trial with NEX-20 that confirmed previous preclinical results and showed a release profile of lenalidomide at various doses up to 21 days. Final safety and tolerability data are expected in October and local adverse events reported to date with NEX-20 have been limited and transient.
- Nanexa AB announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was previously seen in rats. The data show that a release profile of NEX-22 can be obtained for at least 28 days, which was the duration of the pharmacokinetic study and the goal of the study.

Summary of the reporting period 1 April – 30 June 2023

- Turnover amounted to: TSEK 7,655 (211)
- Operating profit (EBIT) amounted to: TSEK -10,067 (-15,854)
- Profit after tax amounted to: TSEK -9,951 (-16,224)
- Earnings per share amounted to: SEK -0,16 (-0,32)
- Cash flow for the period amounted to: TSEK -22,141 (-20,822)
- Cash and cash equivalents at end of period: TSEK 38,358 (66,904)

Summary of the reporting period 1 January – 30 June 2023

- Turnover amounted to: TSEK 15,828 (509)
- Operating profit (EBIT) amounted to: TSEK -18,770 (-28,185)
- Profit after tax amounted to: TSEK -18,553 (-28,594)
- Earnings per share amounted to: SEK -0,31 (-0,56)
- Cash flow for the period amounted to: TSEK -42,824 (-38,756)
- Cash and cash equivalents at end of period: TSEK 38,358 (66,904)

Figures in brackets refer to the corresponding period in the previous year.

The CEO’s comment

During the second quarter of 2023, both our internal projects and partner projects progressed as planned. Significant attention has been devoted to NEX-22, wherein we entered an agreement with the reputable German CRO, Profil. This partnership is in preparation for the start of clinical trials. In NEX-20, we successfully completed the planned recruitment for the first clinical study. Among the partner projects, the collaboration with Novo Nordisk develops strongly and preclinical evaluations are under way also in two other projects.

Riding the wave with NEX-22

Throughout the quarter, our primary focus has been on the development and advancement of NEX-22. We observe that NEX-22 aligns with the vast and rapidly growing market for type 2 diabetes and obesity treatment. As higlighted in the summer letter sent out in July, I elaborated on the underlying data and Nanexa's potential market position. It was gratifying to witness the recent findings from Novo Nordisk's study involving Wegovy (semaglutide – a GLP-1 receptor agonist closely related to NEX-22's liraglutide). The study revealed a significant reduction (-20%) in the risk of major cardiovascular events (e.g. coronary thrombosis and strioke) in individuals with obesity or established cardiovascular disease, without diabetes. This further reinforces the substantial potential of GLP-1 receptor agonists across various indications.

We are content with the progress made in the project. Earlier in the year, we obtained favorable results from the initial preclinical study and, throughout the second quarter, we continued working on preclinical studies and evaluating various formulation options, where we just recently got positive results from a study in minipigs that support our plan to file a clinical trial application during the autumn. As part of the preparations for the first clinical trial, we also established an agreement with the esteemed German contract research organization (CRO), Profil, which specializes in early clinical studies in diabetes and obesity. Their global reputation strengthens our position with both existing and potential partners.

NEX-20 Phase 1 data confirms release profile and NEX-18 proceeds according to plan

During the second quarter, we concluded recruitment for the first clinical trial with NEX-20. We are highly satisfied with the timely completion of this phase and that we received positive pharmacokinetic data in the third quarter, confirming the release profile seen in preclinical animal studies. We anticipate receiving final safety and tolerability data in October. So far, limited and transient reactions at the injection site have been observed and we see good results from preclinical studies with formulations that further limit local reactions.

As for the NEX-18 project, we continue evaluating suitable partners to study potentially improved effects compared to the current Vidaza treatment. This effort includes engagement with a German university. Concurrently, we assess new formulations to eliminate unwanted skin reactions and plan for future clinical trials.

Rewarding and successful partner projects

Our partner projects are progressing as planned and show promise. We initiated the project with Novo Nordisk earlier in the year, and the collaboration is proceeding well. We are developing formulations using their substance and our ALD process, yielding positive outcomes thus far. This joint effort involves a substantial group of experienced pharmaceutical developers from Novo Nordisk, which makes me both proud and content.

Among other partner projects, preclinical animal studies are being conducted where we recently obtained very promising results in one of the collaborations and further animal studies will be conducted during the fall. Beyond the projects themselves, all focused on new and unique long-acting drugs, we value the extensive knowledge exchange with our partners. This invaluable learning enriches our own projects.

Throughout the second quarter and the beginning of the third, we've seized opportunities to connect with potential partners at scientific and partnering conferences in Europe and the USA. The escalating interest in our drug delivery system, PharmaShell®, is evident as we present more data showcasing its unique attributes and its capacity to enhance formulations of biological drugs like peptides and monoclonal antibodies.

Looking ahead

Heading into autumn, I am eagerly anticipating the next steps for NEX-22, where ongoing preclinical evaluation and the application for clinical trial authorization will pave the way for entering the clinical phase in the beginning of next year. We also await final safety data from the study with NEX-20. Among the partner projects, we expect results from several preclinical evaluations, including with Novo Nordisk. These results have the potential to lead to deeper collaborations and significant agreements. With new opportunities and partnerships, I look forward to an exciting autumn as we persist in our constant pursuit of enhancing treatment across numerous disease areas.

The board and management are actively working on the financing issue to find a suitable solution and are evaluating various options that benefit the company and shareholders both in the short and long term. Despite the challenges posed by the financial market, our partnership with Novo Nordisk enhances our prospects. We place great emphasis on cost control and anticipate lower costs in the latter half of the year.

David Westberg, CEO Nanexa

About Nanexa

Nanexa is developing PharmaShell® – a drug delivery-system with major potential

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell®, the high drug load delivery system enabling the next-generation, long-acting injectables atomic layer precision.

Addressing important medical needs and substantial markets

The company has taken important steps in the development in recent years, now driving three drug candidates in as many very interesting areas. All three projects address important medical needs and substantial markets, where the recently launched project, NEX-22, targets treatment of type 2 diabetes, which is huge market with annual sales of USD 50 billion in 7MM (the seven major markets in the Western world).

The NEX-20 and NEX-18 projects are developed to create improved versions and depot formulations of the drugs azacytidine, for treatment of myelodysplastic syndrome (MDS), and lenalidomide, for treatment of multiple myeloma, two types of blood cancer. The properties of the PharmaShell system are utilised to improve these treatments, for example by reducing the burden on patients and caregivers of the inconvenient and costly administration of azacytidine, and by improving compliance to treatment of type 2 diabetes with liraglutide or multiple myeloma with lenalidomide.

The basis for selecting the projects is that there must be a clear medical need, a strong long-term market potential and good technical prerequisites. Nanexa product projects combine already marketed drugs with the company's drug delivery system PharmaShell, enabling formulation of unique long-acting products. The projects' development programs are based on comparison with already approved products, which provides for significantly shorter and less expensive development projects, with significantly lower risk compared to traditional product projects based on new drug substances.

In addition to the own product projects, Nanexa works actively to out-license the PharmaShell technology to pharmaceutical companies that want to create their own unique long-acting products. The company currently has a number of evaluation agreements with other pharmaceutical companies, where the aim of the evaluation work is to establish a basis for further collaboration and out-licensing of the PharmaShell technology for the development of specific new products for the partner companies.

A patented technology with large potential

PharmaShell is based on the Atomic Layer Deposition (ALD) coating technology, which has long been an established technology in the semiconductor industry. The PharmaShell system has a wide range of applications and can be applied to both small-molecule drugs and to biological molecules such as peptides and proteins.

In 2020, Nanexa entered into a collaboration agreement with the world's largest ALD equipment supplier, Applied Materials, Inc., which will facilitate the scale-up of the company's manufacturing of pharmaceuticals based on the PharmaShell system. The first equipment developed by Applied Materials was installed in 2021 and more equipment will be installed in the new pilot plant that Nanexa has designed and built in Uppsala. The pilot plant provides the company with unique capacity for pharmaceutical manufacturing, as it is adapted to meet strict requirements for handling cytostatics and other highly toxic drugs, as well as for so-called aseptic manufacturing, which is critical for the production of depot drugs from biological substances, such as monoclonal antibodies.

Vision

Nanexa will become a world-leading drug development company for long-acting injectables, developing a new generation of innovative drug products enabled by our unique PharmaShell technology.

Business concept

The company will drive the development of innovative drugs from discovery phase through preclinical and clinical development, primarily up to and including completed clinical Proof of Concept in phase II. The objective is subsequently to drive the projects further towards commercialization, together with licence partners or on our own behalf, depending on what is deemed to create the most value for the company.

Nanexa focuses primarily on developing improved versions of existing drugs to achieve new and significantly improved properties that generate value for patients, healthcare and society in general. Thanks to PharmaShell, Nanexa is able to develop products with significant patent protection and high market value. Starting from well-tested pharmaceutical substances means that the biological risk is reduced and the development projects are less costly than for projects with new untested substances. It also makes the registration process easier and shortens the time to market.

Furthermore, the company will license the actual PharmaShell technology to pharmaceutical companies which intend to use it in their own development of unique long-acting drugs. These collaborations contribute revenue for Nanexa as early as the evaluation phase. They also help validate and increase Nanexa's knowledge of the possibilities of the company's technology. In the relatively short term, there are opportunities for extensive development agreements and, in the long run, licensing agreements where there is significant commercial potential.

Comments, Q2 2023

Result and cash flow

Second quarter 2023

Net sales for the quarter amounted to TSEK 7,655 (211), of which TSEK 2,012 (0) is attributable to income generated within the framework of evaluation agreements entered into in respect of the PharmaShell® technology, and TSEK 5,643 concerns allocation of prepaid fee of 4 million dollars related to the exclusivity agreement that was concluded with Novo Nordisk A/S in December 2022. Capitalised development costs amounted to TSEK 9,418 (5,344), attributable mainly to investments in NEX-22, and to a lesser extent in NEX-20, the PharmaShell system and NEX-18.

External project and development costs during the quarter amounted to TSEK -9,128 (-5,469), where the increase compared to the previous year is primarily attributed to significant activity in NEX-22, while substantial resources have also been allocated to NEX-20 and general PharmaShell-development. Other external costs amounted to TSEK -7,190 (-8,036), with the decrease mainly explained by the resolution of the patent dispute in USA in the latter part of 2022, while costs for i.a. financial services and travel were higher than in the second quarter of 2022. Personnel costs for the second quarter amounted to TSEK -7,311 (-5,450), where the increase is mainly due to a rise in the number of employees and to for a change in accrual of variable compensation between the years, which will have no effect on a full-year basis.

The loss for the second quarter amounted to TSEK -9,951 (-16,224).

Cash flow for the quarter amounted to TSEK -22,141 (-20,822). Change in working capital amounted to TSEK -4,925 (-1,753) which is principally explained by a decrease in prepaid income from Novo Nordisk, as well as, to a lesser extent, an increase in prepaid expenses. Cash flow from investment activities amounted to TSEK -10,136 (-10,830), where investments in intangible fixed assets, primarily capitalized development costs, increased significantly, while investments in tangible fixed assets were considerably higher in 2022 due to the relocation to new premises. In the financing activities, new loans taken amounted to TSEK 0 (5,873), while loan amortization amounted to TSEK -551 (-317).

The period January-June 2023

The period's net sales amounted to TSEK 15,828 (509), where TSEK 11,286 (0) pertains to the prepaid exclusivity fee from Novo Nordisk, TSEK 4,029 (0) relates to accrued revenues within partner projects including Novo Nordisk, and TSEK 512 (509) pertains to sensor coating. Capitalized development costs amounted to TSEK 14,712 (10,273), primarily for NEX-22 and NEX-20, and to a lesser extent, the PharmaShell system and NEX-18.

External project and development costs during the period totaled TSEK -15,581 (-10,558), an increase mainly attributed to increased preclinical and clinical development within NEX-22 and NEX-20. Other external costs amounted to TSEK -13,466 (-13,704), where increased costs for items such as rent, financial services, and travel in 2023 offset the reduction of one-time costs in 2022, primarily related to the US patent dispute and also the move and furnishing of new premises. Personnel costs for the period amounted to TSEK -13,385 (-10,143), and have increased due to a growing organization and higher variable compensation costs in 2023.

The loss for the period amounted to TSEK -18,553 (-28,594).

Cash flow for the period January-June 2023 was TSEK -42,824 (-38,756). Changes in working capital amounted to TSEK -13,250 (-1,142), where the decrease is primarily explained by the reduction of prepaid revenues as exclusivity agreement revenues with Novo Nordisk are recognized. Cash flow from investment activities amounted to TSEK -16,515 (-18,951), where investments in intangible fixed assets increased significantly, while investments in tangible fixed assets were considerably higher in 2022 due to the move to new premises. Cash flow from financing activities amounted to TSEK -1,161 (5,353), of which new loans taken amounted to TSEK 0 (5,873), and loan amortization amounted to TSEK -1,102 (-632).

Financial position

Cash and cash equivalents and current investments as of 30/06/2023 amounted to TSEK 38,358 (66,904) and shareholders equity amounted to TSEK 90,483 (122,700).

The company works continuously to secure the long-term financing and based on recent developments, including agreements with and addition of Novo Nordisk to the shareholder list, the board and management see good opportunities to secure continued financing.

The Board considers that the company's current working capital and cash and cash equivalents are sufficient to finance the operations according to the current business plan until the end of 2023, but not for the next 12 months from the submission of this report. To ensure working capital, the company may postpone planned investments and activities, whereby current funds could be sufficient until end of the first quarter of 2024, but may also be financed by raising capital or agreements on licenses and/or exclusivity regarding the PharmaShell technology.

If financing cannot be obtained, there is a material uncertainty factor that could lead to a negative impact on the company's business plan and ability to pursue development at the planned pace, and lead to doubts about the company's ability to continue its operations.

Employees

The number of employees as of June 30, 2023 was 21 (19), of which 8 (7) were women and 13 (12) were men, and the average number of employees (FTE) was 20 (18) in the second quarter of 2023 and 19 (17) during the period January-June 2023. In addition to employed staff, Nanexa regularly hires about ten consultants with specialist expertise.

Related party transactions

During the second quarter 2023, the company has purchased consultancy services from board member Bengt Gustavsson through Sangus Jazz AB for TSEK 383 (662). For the period January-June 2023, the corresponding amount was TSEK 989 (1,266). The consulting services are clearly separated from assignment as a member of the Board of Directors of the company.

The share

Nanexa AB (publ) was listed on the Nasdaq First North Growth Market on 29 May 2020. The share was previously listed on the Spotlight Stock Market since 17 June 2015. As of June 30, 2023, the number of shareholders in Nanexa was 3,003.

Earnings per share

Earnings per share before and after dilution amounted to SEK -0.16 (-0.32) for the second quarter of 2023 and SEK -0.31 (-0.56) for the period January-June 2023.

Number of shares

As of June 30 2023, Nanexa AB (publ) had 60,695,626 (50,695,626) outstanding shares with a quotient value of SEK 0.13. The number of shares at full dilution of outstanding warrants was 63,174,626 (52,191,626).

The average number of shares during the second quarter of 2023 was 60,695,626 (50,695,626) and 60 695 626 (50 695 626) for the period January-June 2023. Including full dilution of outstanding warrants, the average number of shares for the second quarter was 63,174,626 (52,191,626) and 63 174 626 (52 191 626) for the period January-June 2023.

Principles for preparing the report

The interim report has been prepared in accordance with the same accounting principles as in the company's most recent annual report, i.e., in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general recommendations BFNAR 2012:1 Annual Report and Consolidated Accounts (K3).

Upcoming reporting

Nanexa AB provides recurring financial information according to the following plan.

October 27, 2023	Interim report January-September 2023
February 20, 2024	Year-end report 2023

The company’s financial year is 1 January - 31 December.

Other

Annual General Meeting 2023

At Nanexa's annual general meeting on June 9th, it was decided, among other things, to elect Jakob Dynnes Hansen as a new board member, while Bengt Gustavsson and Urban Paulsson had declined reelection, on authorizations for the board to decide on preferential share issue as well as directed share issue, and to establish a warrant-based incentive program for employees. Subsequently, a total of 425,000 warrants were subscribed, corresponding to a maximum dilution of 0.70%.

The new board member Jakob Dynnes Hansen has a solid background in financial management from various roles as CFO within the biotech sector, along with significant experience in financing projects and a strong network of investor contacts. Bengt Gustavsson, who declined reelection to the board of directors, will focus on his operational responsibilities as Medical Directors as part of Nanexa’s management team.

This interim report has not been subject to a comprehensive audit by the company's auditors.

Uppsala 23/08/2023

The board of directors, Nanexa AB

Göran Ando (chairman)

Richard Davis (member) Jakob Dynnes Hansen (member) Eva Nilsagård (member)

Birgit Stattin Norinder (member) Magnus Westgren (member)

David Westberg, CEO Nanexa AB

Income statement

Amounts in TSEK	01/04/2023 – 30/06/2023	01/04/2022 – 30/06/2022	01/01/2023 – 30/06/2023	01/01/2022 – 30/06/2022	01/01/2022 – 31/12/2022
Operating revenue					
Net sales	7,655	211	15,828	509	2,860
Capitalised work on own account	9,418	5,344	14,712	10,273	24,311
Other income	80	92	886	185	1,004
Total revenue	**17,154**	**5,647**	**31,426**	**10,967**	**28,175**
Operating expenses					
External project and development costs	-9,128	-5,469	-15,581	-10,558	-23,769
Other external expenses	-7,190	-8,036	-13,466	-13,704	-28,816
Personnel costs	-7,311	-5,450	-13,385	-10,143	-22,773
Depreciation on intangible and tangible fixed assets	-3,451	-2,431	-6,715	-4,582	-10,504
Other operating costs	-141	-115	-1,049	-165	-294
Total costs	**-27,221**	**-21,501**	**-50,196**	**-39,152**	**-86,156**
Operating profit (EBIT)	**-10,067**	**-15,854**	**-18,770**	**-28,185**	**-57,981**
Profit/loss from financial items					
Interest income and similar income statement items	193	0	369	0	11
Interest expenses and similar income statement items	-106	-372	-211	-413	-666
Total profit/loss from financial items	**87**	**-372**	**157**	**-413**	**-655**
Taxes					
Tax revenue	30	2	60	4	64
Total taxes	**30**	**2**	**60**	**4**	64
Profit/loss for the period	**-9,951**	**-16,224**	**-18,553**	**-28,594**	**-58,571**
Earnings per share (SEK)	-0.16	-0.32	-0.31	-0.56	-1.16

Balance Sheet

Amounts in TSEK	30/06/2023	30/06/2022	31/12/2022
Assets			
Fixed assets			
Intangible fixed assets	76,265	53,744	65,248
Tangible fixed assets	13,875	10,620	15,093
Ongoing new facilities and advances regarding tangible fixed assets	33	5,461	33
Financial fixed assets	155	42	97
Total fixed assets	**90,329**	**69,867**	**80,471**
Current assets			
Stock	2,520	835	487
Current receivables	9,623	9,103	8,055
Short-term deposits	20,010	0	0
Cash and cash equivalents	18,348	66,904	81,182
Total current assets	**50,501**	**76,842**	**89,724**
Total assets	**140,830**	**146,709**	**170,195**
Equity and liabilities			
Equity			
Share capital	7,855	6,561	6,561
Not registered share capital	0	0	1,294
Restricted equity	69,308	48,021	58,649
Share premium reserve	264,477	249,456	264,536
Profit and loss account reserve brought forward	-232,604	-152,744	-163,373
Loss for the period	-18,553	-28,594	-58,571
Total equity	**90,483**	**122,700**	**109,096**
Non-current liabilities			
Liabilities to credit institutions	2,966	5,667	4,068
Other liabilities	6,934	0	18,220
Total non-current liabilities	**9,900**	**5,667**	**22,288**
Current liabilities			
Accounts payable	8,105	9,485	4,661
Other current liabilities	32,342	8,857	34,150
Total current liabilities	**40,446**	**18,342**	**38,811**
Total equity and liabilities	**140,830**	**146,709**	**170,195**
Pledged assets	**7,015**	**7,015**	**7,015**
Assets with retention of title	**6,240**	**7,058**	**6,686**
Contingent liabilities	**0**	**0**	**0**

Cash flow analysis

Amounts in TSEK	01/04/2023 – 30/06/2023	01/04/2022 – 30/06/2022	01/01/2023 – 30/06/2023	01/01/2022 – 30/06/2022	01/01/2022 – 31/12/2022
Current activities					
Operating result	-10,067	-15,854	-18,770	-28,185	-57,981
Adjustments for items not included in cash flow	3,577	2,431	6,926	4,582	10,505
Interest received	67	0	157	0	11
Interest paid	-106	-372	-211	-413	-665
Cash flow from operating activities before change in working capital	**-6,529**	**-13,795**	**-11,898**	**-24,016**	**-48,130**
Cash flow from change in working capital					
Change in inventories and work in progress	-2,352	-835	-2,033	-566	-218
Changes in accounts receivable - trade	-405	749	343	150	-902
Change in receivables	2,069	-5,527	-1,910	-5,680	-3,577
Change in accounts payable - trade	3,029	3,160	3,444	5,756	931
Change in other liabilities	-7,265	700	-13,094	-802	44,025
Total from change in working capital	**-4,925**	**-1,753**	**-13,250**	**-1,142**	**40,259**
Cash flow from current activities	**-11,455**	**-15,548**	**-25,148**	**-25,158**	**-7,871**
Investing activities					
Investments in intangible fixed assets	-10,035	-6,162	-16,329	-11,709	-27,654
Investments in tangible fixed assets	-100	-4,668	-186	-7,242	-7,768
Investments in financial fixed assets	0	0	0	0	0
Cash flow from investment activities	**-10,136**	**-10,830**	**-16,515**	**-18,951**	**-35,422**
Financing activities					
New share issue	0	0	0	0	17,515
Issue costs	0	0	-59	0	-1,140
Borrowings	0	5,873	0	5,985	5,985
Amortisation of loans	-551	-317	-1,102	-632	-3,544
Cash flow from financing activities	**-551**	**5,556**	**-1,161**	**5,353**	**18,814**
Cash-flow for the period	**-22,141**	**-20,822**	**-42,824**	**-38,756**	**-24,478**
Cash and cash equivalents at the beginning of the period	60,500	87,726	81,182	105,660	105,660
Cash and cash equivalents at the end of the period	**38,358**	**66,904**	**38,358**	**66,904**	**81,182**

Changes in equity

Amounts in TSEK	Share capital	Fund for development work	Share premium reserve	Share premium reserve	Profit/Loss brought forward	Profit/Loss for the period	Total equity
Amount as of 01/01/2023	**6,561**	**1,294**	**58,649**	**264,536**	**-163,373**	**-58,571**	**109,096**
Previous year's result					**-58,571**	**58,571**	**0**
New share issue							**0**
Ongoing new issue	1,294	-1,294					**0**
Subscription warrants							**0**
Issue expenses				-59			**-59**
Capitalized development costs for the period			14,712		-14,712		**0**
Depreciation on capitalised development costs for the period			-4,053		4,053		**0**
Profit/loss for the period						-18,553	**-18,553**
Amount as of 30/06/2023	**7,855**	**0**	**69,308**	**264,477**	**-232,604**	**-18,553**	**90,483**

Amounts in TSEK	Share capital	Fund for development work	Share premium reserve	Share premium reserve	Profit/Loss brought forward	Profit/Loss for the period	Total equity
Amount as of 01/01/2022	**6,561**		**40,483**	**249,456**	**-109,208**	**-35,999**	**151,293**
Previous year's result					**-35,999**	**35,999**	**0**
New share issue							**0**
Ongoing new issue		1,294		15,906			**17,200**
Subscription warrants				314			**314**
Issue expenses				-1,140			**-1,140**
Capitalized development costs for the period			24,311		-24,311		**0**
Depreciation on capitalised development costs for the period			-6,145		6,145		**0**
Profit/loss for the period						-58,571	**-58,571**
Amount as of 31/12/2022	**6,561**	**1,294**	**58,649**	**264,536**	**-163,373**	**-58,571**	**109,096**

Pledged assets

	30/06/2023	30/06/2022	31/12/2022
Corporate mortgages	7,015	7,015	7,015

Assets with retention of title

	30/06/2023	30/06/2022	31/12/2022
Assets with retention of title	6,240	7,058	6,686

Contingent liabilities

	30/06/2023	30/06/2022	31/12/2022
Other contingent liabilities	0	0	0

Contact

David Westberg
CEO
+46 709-42 83 03
david.westberg@nanexa.se

This information is such that Nanexa is obliged to publish in accordance with the EU Market Abuse Regulation.
The information was submitted, through the above contact persons, for publication on 23 August 2023 at 08:00 CEST.

Nanexa AB

Virdings Allé 2, SE-754 50 Uppsala, Sweden
Phone: +46 (0) 18 100 300
Org nr. 556833-0285
info@nanexa.se